Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DME7IVL)

• Drug Name: Xmab-7195 Drug Info
• Synonyms: IgE inhibitor (asthma/allergy), Xencor

Indication

Disease Entry	ICD 11	Status	REF
Asthma	CA23	Phase 1	[1]

• Cross-matching ID: TTD Drug ID: DME7IVL

Molecule-Related Drug Atlas

Drug(s) Targeting Immunoglobulin E (IgE)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Ligelizumab	DM103O8	Chronic idiopathic urticaria	EB00.1	Phase 3	[3]
MEMP1972A	DMUMCWS	Allergic rhinitis	CA08.0	Phase 2	[4]
PF-06444752	DM9UZTO	Asthma	CA23	Phase 1	[5]
MEDI4212	DMBI4EN	Asthma	CA23	Phase 1	[6]
AVP-13358	DM8CYJ1	Rhinitis	FA20	Phase 1	[7]
TAK-201	DM8S173	Allergy	4A80-4A85	Discontinued in Phase 2	[8]
TEI-9874	DMXM3B4	Allergy	4A80-4A85	Terminated	[9]
IGE-026	DM16S98	Allergic rhinitis	CA08.0	Terminated	[10]
D17.4	DMSON1P	Myasthenia gravis	8C6Y	Investigative	[11]
IGEL1.2	DMOU234	Allergy	4A80-4A85	Investigative	[11]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Immunoglobulin E (IgE)	TTYJQTF	NOUNIPROTAC	Inhibitor	[2]

References

• [1] ClinicalTrials.gov (NCT02148744) Safety and Tolerability of XmAb7195 in Adult Healthy Volunteers and Adult Subjects With a History of Allergic Rhinitis and/or Allergic Conjunctivitis and/or Atopic Dermatitis. U.S. National Institutes of Health.
• [2] Clinical pipeline report, company report or official report of Xencor.
• [3] Clinical pipeline report, company report or official report of Novartis.
• [4] International Nonproprietary Names for Pharmaceutical Substances (INN). WHO Drug Information, Vol. 25, No. 4, 2011
• [5] ClinicalTrials.gov (NCT01723254) A Study To Assess The Safety And Tolerability Of Different Doses Of PF-06444753 And PF-06444752 In Subjects With Allergic Rhinitis. U.S. National Institutes of Health.
• [6] A novel IgE-neutralizing antibody for the treatment of severe uncontrolled asthma. MAbs. 2014 May-Jun;6(3):756-64.
• [7] Novel 2-(substituted phenyl)benzimidazole derivatives with potent activity against IgE, cytokines, and CD23 for the treatment of allergy and asthma. J Med Chem. 2004 Dec 16;47(26):6451-4.
• [8] Adecatumumab: an anti-EpCAM monoclonal antibody, from the bench to the bedside. Expert Opin Biol Ther. 2010 Jun;10(6):951-8.
• [9] Effect of TEI-9874, an inhibitor of immunoglobulin E production, on allergen-induced asthmatic model in rats. Eur J Pharmacol. 2000 Aug 25;402(3):287-95.
• [10] IgE inhibition as a therapy for allergic disease. Int Arch Allergy Immunol. 1999 Feb-Apr;118(2-4):112-5.
• [11] Therapeutic applications of aptamers. Expert Opin Investig Drugs. 2008 Jan;17(1):43-60.